1. Home
  2. IMUX vs INVE Comparison

IMUX vs INVE Comparison

Compare IMUX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • INVE
  • Stock Information
  • Founded
  • IMUX 2016
  • INVE 1990
  • Country
  • IMUX United States
  • INVE United States
  • Employees
  • IMUX N/A
  • INVE N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • INVE Computer peripheral equipment
  • Sector
  • IMUX Health Care
  • INVE Technology
  • Exchange
  • IMUX Nasdaq
  • INVE Nasdaq
  • Market Cap
  • IMUX 86.3M
  • INVE 86.5M
  • IPO Year
  • IMUX N/A
  • INVE 1997
  • Fundamental
  • Price
  • IMUX $0.98
  • INVE $3.48
  • Analyst Decision
  • IMUX Strong Buy
  • INVE Strong Buy
  • Analyst Count
  • IMUX 6
  • INVE 2
  • Target Price
  • IMUX $12.67
  • INVE $7.25
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • INVE 39.5K
  • Earning Date
  • IMUX 02-20-2025
  • INVE 03-11-2025
  • Dividend Yield
  • IMUX N/A
  • INVE N/A
  • EPS Growth
  • IMUX N/A
  • INVE N/A
  • EPS
  • IMUX N/A
  • INVE 3.10
  • Revenue
  • IMUX N/A
  • INVE $104,217,000.00
  • Revenue This Year
  • IMUX N/A
  • INVE N/A
  • Revenue Next Year
  • IMUX N/A
  • INVE N/A
  • P/E Ratio
  • IMUX N/A
  • INVE $1.12
  • Revenue Growth
  • IMUX N/A
  • INVE 70.57
  • 52 Week Low
  • IMUX $0.92
  • INVE $2.95
  • 52 Week High
  • IMUX $2.11
  • INVE $9.24
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • INVE 43.25
  • Support Level
  • IMUX $0.94
  • INVE $3.50
  • Resistance Level
  • IMUX $1.02
  • INVE $3.82
  • Average True Range (ATR)
  • IMUX 0.06
  • INVE 0.18
  • MACD
  • IMUX 0.00
  • INVE -0.01
  • Stochastic Oscillator
  • IMUX 44.96
  • INVE 21.82

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

Share on Social Networks: